Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Trading 0.4% Higher – Should You Buy?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) traded up 0.4% on Monday . The company traded as high as $27.00 and last traded at $27.00. 100 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 400 shares. The stock had previously closed at $26.90.

Analyst Ratings Changes

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research note on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Stock Up 0.4 %

The stock has a market cap of $9.61 billion, a price-to-earnings ratio of 25.96 and a beta of 0.54. The business has a fifty day moving average of $28.79 and a 200 day moving average of $29.03. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.91 and a quick ratio of 0.62.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.